XTL Biopharmaceuticals Ltd. H2K2.F Stock
XTL Biopharmaceuticals Ltd. Price Chart
XTL Biopharmaceuticals Ltd. H2K2.F Financial and Trading Overview
| XTL Biopharmaceuticals Ltd. stock price | 2.04 EUR |
| Previous Close | 1.01 EUR |
| Open | 1.08 EUR |
| Bid | 1.13 EUR x 0 |
| Ask | 1.22 EUR x 0 |
| Day's Range | 1.08 - 1.08 EUR |
| 52 Week Range | 0.94 - 1.67 EUR |
| Volume | 150 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 6.67M EUR |
| Beta (5Y Monthly) | 0.934931 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.03 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
H2K2.F Valuation Measures
| Enterprise Value | 2.63M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.8 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.982 |
Trading Information
XTL Biopharmaceuticals Ltd. Stock Price History
| Beta (5Y Monthly) | 0.934931 |
| 52-Week Change | -19.84% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.67 EUR |
| 52 Week Low | 0.94 EUR |
| 50-Day Moving Average | 1.06 EUR |
| 200-Day Moving Average | 1.16 EUR |
H2K2.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 5.45M |
| Float | 4.13M |
| Short Ratio | N/A |
| % Held by Insiders | 14.44% |
| % Held by Institutions | 4.60% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -11.088% |
| Return on Equity (ttm) | -62.13% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -881000 EUR |
| Net Income Avi to Common (ttm) | -2773000 EUR |
| Diluted EPS (ttm) | -0.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.88M EUR |
| Total Cash Per Share (mrq) | 0.53 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 12.207 |
| Book Value Per Share (mrq) | 0.6 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of XTL Biopharmaceuticals Ltd.
| Country | Germany |
| State | N/A |
| City | Ramat Gan |
| Address | 5 Badner Street |
| ZIP | 5218102 |
| Phone | 972 3 611 6600 |
| Website | https://www.xtlbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Q&A For XTL Biopharmaceuticals Ltd. Stock
What is a current H2K2.F stock price?
XTL Biopharmaceuticals Ltd. H2K2.F stock price today per share is 2.04 EUR.
How to purchase XTL Biopharmaceuticals Ltd. stock?
You can buy H2K2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for XTL Biopharmaceuticals Ltd.?
The stock symbol or ticker of XTL Biopharmaceuticals Ltd. is H2K2.F.
Which industry does the XTL Biopharmaceuticals Ltd. company belong to?
The XTL Biopharmaceuticals Ltd. industry is Biotechnology.
How many shares does XTL Biopharmaceuticals Ltd. have in circulation?
The max supply of XTL Biopharmaceuticals Ltd. shares is 5.74M.
What is XTL Biopharmaceuticals Ltd. Price to Earnings Ratio (PE Ratio)?
XTL Biopharmaceuticals Ltd. PE Ratio is now.
What was XTL Biopharmaceuticals Ltd. earnings per share over the trailing 12 months (TTM)?
XTL Biopharmaceuticals Ltd. EPS is -0.03 EUR over the trailing 12 months.
Which sector does the XTL Biopharmaceuticals Ltd. company belong to?
The XTL Biopharmaceuticals Ltd. sector is Healthcare.